



CEO: Itaru Tanimura

TSE Ticker Code: 2413

Contact: Anna Kiso, Investor Relations (m3-ir@m3.com)

**M3, Inc. to Acquire Neues Co., Ltd.,
~ Evolving as Japan's Leading Comprehensive Clinical Trial Services Provider ~**

M3, Inc. announced that today its Board of Directors resolved on a transaction to make of NEUES Co., Ltd. ("Neues" below), which operates one of the largest SMO business in Japan, a subsidiary by purchasing its shares.

I. Strategic Reasons for the Acquisition

Neues is an SMO (Note 1) operating a clinical trial business with 20 offices across Japan and centers in Tokyo, Osaka, and Fukuoka. They are an industry leader with affiliate institutions reaching approximately 800 facilities, and track record across a wide variety of clinical cases.

Meanwhile, M3, Inc. operates a portal site, "m3.com," designed for medical professionals. With over 250 thousand physician members, the site offers various services including "Mr. Rep," which provides continuous information through voluntary reception by those members. Within the clinical trial segment, services centered around "Mr. Finder," which excavates potential institutions and patients, optimize clinical trial efficiency by utilization of the internet. Other related services are carried out via our CRO (Note 2) and SMO group companies. e-SMO Inc. is one such SMO within our group affiliated with over 400 institutions.

By acquiring Neues, our group will expand our affiliate relationships, increase our ability to incorporate more clinical cases, as well as obtain high quality human resources. The group's growing clinical trial business will become a leading presence within the industry in terms of affiliate institutions and manpower, and we anticipate that our expanded operations will increase the volume and scale of projects we undertake. M3 group intends to further contribute towards our affiliate institutions and our pharmaceutical company clientele.

(Note 1) SMO

SMO (Site Management Organization) is an organization that provides clinical trial related services based on GCP standards via contracts with clinical sites (medical facilities) in order to ensure appropriate and smooth execution of often cumbersome trials carried out at medical facilities. We lighten the workload on the staff while improving quality and speed by supporting the related activities of doctors, nurses, and administrative departments involved in the clinical trial.

(Note 2) CRO

CRO (Contract Research Organization) is an organization that provides drug development services outsourced on a contract basis. We contract services spanning across nearly the entire range of operations related to clinical trials conducted by pharmaceutical or similar companies.

II. Outline of Subsidiary to Be Transferred (Neues)

(1)	Name	NEUES Co., Ltd.										
(2)	Head office	1-6-6 Yaesu, Chuo-ku, Tokyo, Japan										
(3)	Representative	Toshiaki Amamoto, CEO										
(4)	Main Business	SMO (Site Management Organization) business										
(5)	Paid-in Capital	70,300,000 Yen										
(6)	Establishment	December 2, 1996										
(7)	Major shareholders and shareholding ratio	<table> <tr> <td>Toshiaki Amamoto</td> <td>32.0%</td> </tr> <tr> <td>Ryuji Urae</td> <td>30.9%</td> </tr> <tr> <td>LSI Medience Corporation</td> <td>9.1%</td> </tr> <tr> <td>K.K. Random Square</td> <td>6.1%</td> </tr> </table>			Toshiaki Amamoto	32.0%	Ryuji Urae	30.9%	LSI Medience Corporation	9.1%	K.K. Random Square	6.1%
Toshiaki Amamoto	32.0%											
Ryuji Urae	30.9%											
LSI Medience Corporation	9.1%											
K.K. Random Square	6.1%											
(8)	Relationship between listed company M3, Inc. and Neues	Capital Ties	There are no capital ties between M3, Inc. and Neues that require reporting. M3, Inc.'s subsidiary, MEDISCIENCE PLANNING INC. (MPI), owns 2.6% of total outstanding shares of Neues, equivalent to 40 shares. Furthermore, MPI owns 49% of total outstanding shares of RINSYOYAKU.INC., a subsidiary of Neues, equivalent to 98 shares.									
		Personnel Ties	There are no personnel ties between M3, Inc. and Neues that require reporting. Akinori Urae who is a board member of M3, Inc. is also a board member of RINSYOYAKU.INC. which is a subsidiary of Neues.									
		Business Ties	There are no business ties between M3, Inc. and Neues that require reporting. Operational transaction ties between the consolidated subsidiaries of M3, Inc. and Neues exist.									
(9)	Neues's Performance and Financial Positions in the Past Three Years											
		Fiscal year ending October 2011	Fiscal year ending October 2012	Fiscal year ending October 2013								
	Net Assets	629 Million Yen	713 Million Yen	689 Million Yen								
	Total Assets	2,044 Million Yen	2,086 Million Yen	2,563 Million Yen								
	Net Asset Per Share	407,300 Yen	461,538 Yen	446,236 Yen								
	Net Sales	3,435 Million Yen	4,032 Million Yen	4,040 Million Yen								
	Operating Profit	▲264 Million Yen	28 Million Yen	5 Million Yen								
	Ordinary Profit	▲249 Million Yen	41 Million Yen	12 Million Yen								
	Net Profit	▲234 Million Yen	83 Million Yen	▲23 Million Yen								
	Net Profit per Share	▲151,817 Yen	54,237 Yen	▲15,301 Yen								
	Annual Dividend per Share	2,500 Yen	0 Yen	0 Yen								

III. Outline of Seller of Shares

(i) Individual shareholders including Toshiaki Amamoto

(1)	Name	12 Shareholders including Toshiaki Amamoto
(2)	Address	Chuo-ku, Fukuoka-shi, Fukuoka-ken; others
(3)	Shareholders' relationship with M3 Group	Toshiaki Amamoto holds a minority stake in outstanding shares of M3, Inc. There are no other capital, personnel or business ties between M3, Inc. and related shareholders that require reporting.

Name and address of shareholders other than Toshiaki Amamoto will not be disclosed upon their request.

(ii) K.K. Random Square

(1)	Name	K.K. Random Square	
(2)	Address	6-18, Tenyamachi, Hakata-ku, Fukuoka-ken	
(3)	Title and Name of Representative	Toshiaki Amamoto, CEO	
(4)	Description of Business	Real Estate Leasing Business, Preventive Elderly Care Support Business, others	
(5)	Paid-in Capital	10,000,000 Yen	
(6)	Establishment	May 29, 2002	
(7)	Net Assets	– Undisclosed upon request of K.K. Random Square	
(8)	Total Assets	– Undisclosed upon request of K.K. Random Square	
(9)	Major shareholders and shareholding ratio	– Undisclosed upon request of K.K. Random Square	
(10)	Relationship between the M3 Group and K.K. Random Square	Capital Ties	K.K. Random Square owns 0.19% of outstanding shares of M3, Inc., equivalent to 574,000 shares.
		Personnel Ties	There are no personnel ties between M3, Inc. and K.K. Random Square that require reporting.
		Business Ties	MPI, a subsidiary of M3, Inc., leases real estate from K.K. Random Square.
		Status as a Related Party	There are no ties between K.K. Random Square and M3, Inc. that require reporting.

(iii) MEDISCIENCE Planning Inc.

(1)	Name	MEDISCIENCE PLANNING INC. (MPI)
(2)	Address	1-11-44, Akasaka, Minato-ku, Tokyo
(3)	Title and Name of Representative	Akinori Urae, Board Chairman and CEO
(4)	Description of Business	CRO (Clinical Research Organization) business, others
(5)	Paid-in Capital	50,000,000 Yen
(6)	Establishment	September, 1982
(7)	Net Assets	2,199,869,000 Yen
(8)	Total Assets	4,307,471,000 Yen
(9)	Major shareholders and shareholding ratio	M3, Inc. 100%

(10) Relationship between M3 Group and MPI	Capital Ties	M3, Inc. owns all outstanding shares (2,547,565 shares) of MPI.
	Personnel Ties	Two board members of M3, Inc. are also board members of MPI, and one employee of M3, Inc. is an auditing officer at MPI. Furthermore, there are secondment relationships amongst M3, Inc., its consolidated subsidiaries, and MPI.
	Business Ties	MPI has business ties with M3, Inc. and its subsidiaries including consignment and contracting of monitoring staff. Furthermore, MPI consigns translation business to an equity method affiliate of M3, Inc.
	Status as a Related Party	MPI is a consolidated subsidiary of M3, Inc. and is deemed a related party.

(Attn.) Only shareholders expected to enter the share purchase on December 19, 2014 are listed above.

(iv) Others

Currently, we have consent on share transfers from 14 shareholders (total shares held: 1,406 shares, ownership ratio: 90.9%) including Toshiaki Amamoto, K.K Random Square, and MEDISCIENCE Planning Inc. We plan to gain consent on the share transfer from the remaining one shareholder (total shares held: 140 shares, ownership ratio: 9.1%) by April 1, 2015 (tentative closing date).

IV. Number of Shares held, Purchase Amount, and Share Ownership Before and After Purchase

(1) Shares held before purchase	40 shares (Includes indirect ownership of 40 shares) (Number of voting shares: 40 shares; includes indirect ownership of 40 shares) (Ratio of voting rights: 2.6%; includes voting rights from indirect ownership)
(2) Shares purchased	1,406 shares (includes 40 shares of indirect ownership) (Number of voting shares: 1,406 votes; includes 40 votes of indirect ownership) (Ratio of voting rights: 90.9%; includes voting rights from indirect ownership)
(3) Purchase amount	Common shares of Neues: 182 Million Yen Advisory and Other Fees: Approximated to be a maximum of 10 Million Yen Total: Approximately 192 Million Yen
(4) Shares held after purchase	1,406 shares (Number of voting shares: 1,406 votes) (Ratio of voting rights: 90.9%)

V. Schedule

(1) Board of Directors Resolution Date	December 19, 2014
(2) Signing of Share Purchase Agreement	December 19, 2014
(3) Transfer of Shares	April 1, 2015 (tentative)

VI Outlook

Impact from the purchase of shares of Neues will have minimal impact on M3, Inc.'s consolidated performance in fiscal year ending March 31, 2015.

(Reference) Forecast of consolidated cumulative results for fiscal year ending March 31, 2015

(Unit: Million Yen)

	Net Sales	Operating Profit	Pre-tax Profit	Net Profit
Forecast for fiscal year ending March 2015	50,000	15,000	15,000	9,000

Disclaimer:

The information contained in this report was originally prepared and published by the Company in Japanese to be submitted to the Tokyo Stock Exchange. This English translation is for your convenience only.